13 juni 2011: ik ben kanker-actueel aan het herzien en kwam onderstaand artikel tegen. Een kleine zoektocht in pubmed laat zien dat mifeprestone nog steeds een middel is dat wereldwijd de interesse heeft i.v.m. controle van kanker. Twee van de meest recente studies zijn onderaan toegevoegd.

23 augustus 2009: Bron: Pubmed en met dank aan Vincent, een Amerikaanse arts

Mifeprestone - een abortuspil ( oraal 200 mg. per dag ingenomen) - stopt groei van tumoren bij twee darmkankerpatienten met zeer veruitgezaaide darmkanker en beperkte levensduur en verlengt daarmee hun leven hoog significant. En er kwamen geen nieuwe tumoren bij. Mifeprestone staat bekend als een anti progesteron middel. Ook andere studies met muizen maar ook met patienten met andere vormen van kanker, bv. endometriosekanker (fase II studie) , borstkanker en leyocarcinoom en sarcomen en in dierpoeven met leukemie bv. laat zien dat mifeprestone de tumorgroei stopt. Het doet de aanwezige kanker echter niet verdwijnen. Toch is de eerste publicatie hierover die ik kon vinden al gedaan in 1998 en nu melden twee recente publicaties uit mei 2009 deze opmerkelijke resultaten. Wat eerst erbij werd gezegd is dat het wel tumoren moeten zijn met positieve progestronreceptoren. Maar een recente studie uit januari 2009 zegt dat mifeprestone ook blijkt te werken met niet positieve progesteron receptoren. Ik heb er te weinig verstand van om uit te leggen wat dit precies betekent maar vraag dit aan uw arts aub.

Achtereenvolgens een aantal abstracten die ik heb geselecteerd. Als u zelf gaat experimenteren, Mifeprestone is verkrijgbaar in elke apotheek in Nederland, doe dat dan aub wel onder begeleiding van een arts. Lees ook onze disclaimer

1: Cancer. 2009 May 1;115(9):1867-74. Links

Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.

Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T.

Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

BACKGROUND:: The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS).

METHODS:: Mifepristone (RU-486; 200 mg orally) was given daily to patients with progesterone receptor-positive advanced or recurrent endometrioid adenocarcinoma or LGESS. Patients were evaluated every 4 weeks for toxicity and response. Quality-of-life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy.

RESULTS:: Twelve of 13 enrolled patients were evaluable in the first phase of accrual. Stable disease was noted in 3 of 12 patients (at 8 weeks, 12 weeks, and > or =77 weeks, respectively), and the median time to disease progression was 48 days. Among the patients who had stable disease, 2 women had endometrioid endometrial cancer, and 1 woman had LGESS. No partial or complete responses were observed. The most frequent grade 1 and 2 toxicities were anorexia, fatigue, and mood alterations observed in 50%, 50%, and 58% of patients, respectively. The most common grade 3 toxicities were fatigue and dyspnea observed in 25% and 17% of patients, respectively. One patient experienced grade 4 dyspnea. Thirty-three percent of patients had asymptomatic elevations of corticotropin. No serious treatment-related adverse events occurred. There were no significant changes in quality of life.

CONCLUSIONS:: Single-agent mifepristone used in the treatment of recurrent endometrioid adenocarcinoma or LGESS resulted in a stable disease rate of 25%. One patient who had a biopsy-positive disease recurrence remained stable at 77 weeks. Although mifepristone was tolerated well, as a single agent, it provided limited response as a single agent in women with progesterone receptor-positive uterine tumors. Recently, was been recognized that biologic agents used as single agents may result only in stable disease unless they are combined with cytotoxic agents. The authors concluded that further research into the best mode of application for mifepristone in the treatment of endometrial cancer is needed. Cancer 2009. (c) 2009 American Cancer Society.

PMID: 19241422 [PubMed - indexed for MEDLINE]

1: Anticancer Res. 2009 May;29(5):1611-3. Links

Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.

Check JH, Dix E, Sansoucie L, Check D.

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, The University of Medicine and Dentistry of New Jersey, NJ, U.S.A. laurie@ccivf.com

BACKGROUND: Mifepristone, a progesterone receptor antagonist has been found to improve the length and quality of life in various spontaneous murine cancer models including tumors without progesterone receptors theoretically by inhibiting an immunomodulatory protein that suppresses natural killer cell function in the tumor microenvironment.

MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases.

RESULTS: Both patients not only survived far longer than expected but had marked improvement in their quality of life similar to mice. Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow. The drug was extremely well tolerated.

CONCLUSION: The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer. A larger controlled study is needed.

1: Clin Exp Obstet Gynecol. 2007;34(4):207-11. Links

Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity.

Check JH, Sansoucie L, Chern J, Amadi N, Srivastava M, Larece K.

PURPOSE: To propose a novel concept that progesterone receptor antagonists, e.g., mifepristone, may prove effective in treating a variety of cancers--even those not shown to be hormonally dependent or possessing progesterone receptors.

METHODS: Multiple human leukemia cell lines were evaluated for mRNA expression of an immunomodulatory protein called the progesterone-induced blocking factor (PIBF) that suppresses natural killer (NK) cell activity during normal pregnancy. Furthermore, we evaluated the effects of progesterone (P) and mifepristone in PIBF protein expression. Finally, the effect of mifepristone treatment of mice with advanced leukemia was evaluated.

RESULTS: All tumor cell lines evaluated were found to express mRNA for PIBF and some were found to even express the PIBF protein. The addition of P to the media increased the expression of PIBF and mifepristone downregulated its expression. Treatment of mice with spontaneous leukemia when they already had extensive disease seemed to increase the length and quality of their life.

CONCLUSIONS: These data and other experience with mice with lung cancer and some anecdotal human cancer experience suggest that various cancers may utilize similar mechanisms used by the fetus to escape NK cell surveillance. Mifepristone and other progesterone receptor antagonists may deserve a clinical trial in human cancer even where there is no knowledge of the presence of progesterone receptors.

Mifepristone (RU486), a pure antiprogesterone drug, in combination with vinblastine for the treatment of progesterone receptor-positive desmoid tumor

Source: Springerlink: >>>>>Read here the full studyreport

Abstract

We report the case of a patient who developed a desmoid tumor following total proctocolectomy and J-pouch reconstruction that was unresponsive to any medical treatment. Based on estrogen receptor alpha (ERα) and progesterone receptor (PR) evaluation (ERα-negative, but PR-positive), treatment with mifepristone, a pure antiprogesterone drug, was initiated, and partial tumor regression was achieved.

Source: Anticancer Res. 2010 Feb;30(2):623-8.

Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.

Check JH, Dix E, Cohen R, Check D, Wilson C.

Source

The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Camden, New Jersey, USA.

Abstract

BACKGROUND:

Mifepristone has been demonstrated to improve longevity and quality of life in mice with spontaneous murine cancer without progesterone receptors and in human colon cancer. The present study evaluated the palliative effect of mifepristone in a variety of different types of human cancer.

PATIENTS AND METHODS:

Mifepristone was given at 200 mg daily orally with permission from the Food and Drug Administration to people with widely metastatic human cancer no longer responsive to other chemotherapy regimens.

RESULTS:

Improvement in pain and energy and/or length of life was found in thymic epithelial cell carcinoma, transitional cell carcinoma of the renal pelvis, leiomyosarcoma, pancreatic carcinoma, malignant fibrous histiocytoma and another case of adenocarcinoma of the colon.

CONCLUSION:

Our data demonstrate a palliative role for the use of mifepristone in cancer therapy. Progesterone receptor antagonists should be given a therapeutic trial in larger controlled studies of various malignancies in humans.